pharmacology
Do amygdala astrocytes help or hurt chronic neuropathic pain?
Open access · cc by · source: Europe PMC
CeA GFAP rose at 4 weeks (not 1 week) after SNL; inhibiting astrocytes with FCA increased CeLC excitability and facilitated mechanical/affective pain behaviors, suggesting beneficial astrocyte roles.
Key findings
Astrocyte markers increased chronically (4 weeks post-SNL). Slice FCA (100 µM, 1 h) raised excitability via Ih changes without major PB-CeLC synaptic shifts. Intra-CeA FCA facilitated mechanical withdrawal and evoked vocalizations; GFAP (not NeuN) fell, supporting selective astrocyte inhibition.
Methodology
Measured CeA GFAP protein/mRNA after spinal nerve ligation, then used fluorocitric acid (FCA) in CeLC slices and intra-CeA injections to test effects on excitability, PB-CeLC synapses, and pain-like behaviors in chronic neuropathic rats.
Limitations
Rodent SNL findings may not translate directly to human chronic pain therapies; FCA is a tool compound, not a clinical drug.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.